CapsoVision, Inc. (CV)
CVNASDAQ-CMBiotechnology: Electromedical & Electrotherapeutic Apparatus
$6.27
0.0000 (0.00%) today
Closed, Nov 12, 4:00 PM ET
- Market cap
- $333.54m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $4.50 to $15.37
- Average volume
- –
- Previous close
- $6.27
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $9.00, +43.5% from here
Earnings
next estimate $-0.1500Next report
Mar 2026
–
Jun 2026
–
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $3.54m | $3.92m | $2.79m | $3.64m |
| Gross profit | $1.91m | $1.95m | $1.33m | $1.87m |
| Operating income | -$8.02m | -$7.46m | -$7.09m | -$7.58m |
| Net income | -$7.92m | -$7.39m | -$7.03m | -$7.48m |
Last four quarters: revenue $13.89m, margin -214.7%, free cash flow –
News
8 latest- CapsoVision (CV) Q3 2026 Earnings Call TranscriptThe Motley Fool · 2 hours ago
- CapsoVision, Inc Q3 Loss Drops RTTNews · 11 hours ago
- 10x Genomics (TXG) Reports Q3 Loss, Beats Revenue EstimatesZacks · Nov 5, 2026
- CapsoVision Maps AI Capsule Push Into Colon, Pancreatic Cancer ScreeningMarketBeat · Oct 24, 2026
- Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data RTTNews · Oct 2, 2026
- CapsoVision's AI Highlights Receives FDA Clearance For CapsoCam Plus RTTNews · Sep 28, 2026
- CapsoVision Wins FDA Clearance For AI Highlights Tool RTTNews · Sep 28, 2026
- After Hours Most Active for Sep 25, 2026 : FTXN, ABUS, FTXH, CMCSA, NVDA, CSCO, JPM, BMNR, EQT, CNP, PFE, CVSNASDAQ.com · Sep 25, 2026
The company
CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and screening of gastrointestinal diseases. Its flagship product, CapsoCam Plus, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video review. The Company's next pipeline product, CapsoCam Colon with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics.
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- capsovision.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.